Indications, Dosages and Administration of FDA-Approved Drugs — CPB 0156 | AETNA Coverage Update

Aetna modified CPB 0156, its foundational coverage policy for FDA-approved drug indications and dosages, effective January 22, 2026. Here's what billing teams need to know.

Aetna, a CVS Health company, updated CPB 0156 — the Clinical Policy Bulletin that sets the baseline rules for medical necessity across virtually every FDA-approved prescription drug it covers under commercial medical plans. This policy doesn't govern a single drug or drug class. It sets the framework that applies when no other Aetna CPB exists for a specific product. Because CPB 0156 in the Aetna system functions as the default standard, changes here ripple across dozens of specialties and thousands of drug claims. No specific CPT or HCPCS codes are listed in this policy — its scope is deliberately broad.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Indications, Dosages and Administration of FDA-Approved Drugs
Policy Code	CPB 0156
Change Type	Modified
Effective Date	January 22, 2026
Impact Level	High
Specialties Affected	All specialties billing drug administration under commercial Aetna plans — oncology, rheumatology, neurology, infusion therapy, and any specialty using off-label or compendium-supported drug indications
Key Action	Audit your medical necessity documentation for any drug claim where the indication is supported by compendia or trial data rather than FDA labeling

---

Aetna FDA-Approved Drug Coverage Criteria and Medical Necessity Requirements 2026

CPB 0156 is the Aetna drug coverage policy that determines medical necessity when no drug-specific CPB applies. Think of it as the backstop rule. If Aetna hasn't written a dedicated bulletin for a drug, this policy governs.

The updated policy sets out three paths to medical necessity for an indication. The drug must meet at least one of them.

Path 1: FDA-approved for the indication. This is the cleanest path. If the drug carries FDA approval for the specific indication you're billing, Aetna considers it medically necessary under this policy. No further evidence is required.

Path 2: Compendia support. Aetna accepts five compendia as authoritative. They are:

If at least one of these lists the drug as accepted for the indication, Aetna considers it medically necessary. Oncology teams already know this list well — it's the same standard used in most chemotherapy coverage determinations. The NCCN compendium inclusion is particularly significant for off-label cancer drug use.

Path 3: Peer-reviewed clinical trial evidence. A well-designed Phase III or Phase IIb (single-center controlled) trial published in a nationally recognized peer-reviewed journal supports medical necessity. One qualifying trial is enough.

There's a critical fourth condition for combination drug therapy. When you're billing a drug used in combination with other agents for a specific indication, the safety and efficacy of the combination must be supported by reliable peer-reviewed evidence. FDA approval of each drug individually is not sufficient. The combination itself needs evidence.

This is where claim denial risk is highest for billing teams. A physician might prescribe two individually FDA-approved drugs together for an indication where no published trial supports the specific combination. Under CPB 0156, that combination fails the medical necessity test.

Dosage Standards Under CPB 0156

Aetna's coverage policy also governs what counts as a medically necessary dosage. Three parallel standards apply.

First, the dosage in FDA-approved labeling. Second, the dosage recommended by one of the five compendia listed above. Third, a dosage demonstrated safe and effective in one or more well-designed controlled trials in peer-reviewed literature.

This matters for reimbursement when physicians dose outside the labeled range. If you're billing drug administration at a dose above or below the FDA label, your documentation needs to point to compendia support or a qualifying trial. Without it, Aetna has grounds to deny.

When Continued Use Fails Medical Necessity

CPB 0156 draws a clear line on continued therapy. Continued use of a drug is not medically necessary when a member:

This is standard language, but it creates a documentation obligation. If a patient continues on therapy after a documented failure or intolerance, your team needs to show either a new clinical rationale or that a different policy (a more specific CPB) governs.

Prior Authorization and Benefit Plan Overlap

CPB 0156 explicitly states it does not limit Aetna's ability to require prior authorization for any product covered under this policy. Prior auth requirements exist independently of whether a drug meets medical necessity under CPB 0156.

Read that again. A drug can be medically necessary under this coverage policy and still require prior authorization before Aetna will pay. These are two separate gates.

Aetna also notes that pharmacy benefit management programs and formulary restrictions may apply. Check the member's specific benefit plan before billing. The CPB sets the floor — the plan document may raise the bar.

---

Coverage Indications at a Glance

This policy doesn't govern specific indications. It sets the evidentiary standards that determine whether any indication qualifies. The table below summarizes the coverage framework.

---

Aetna FDA-Approved Drug Billing Guidelines and Action Items 2026

The effective date for this update is January 22, 2026. If you bill drug administration to Aetna commercial plans, these steps apply now.

1. Audit your off-label drug documentation before submitting new claims.
For any drug you're billing under an off-label indication, confirm you have documentation of compendia support or qualifying trial evidence. "The physician ordered it" is not sufficient. Pull the compendia reference and attach it to the file.

2. Flag combination therapy claims for extra review.
If your practice bills combination drug regimens, build a review step into your charge capture process. Each combination needs peer-reviewed evidence supporting the specific combination, not just the individual drugs. This is the highest-risk area for claim denial under CPB 0156.

3. Update your dosage documentation protocols.
When billing drug administration at doses outside FDA labeling, your documentation must reference compendia support or a qualifying trial. Add a documentation checklist item for non-standard dosing before claims go out.

4. Confirm prior authorization status separately from medical necessity.
Medical necessity under CPB 0156 and prior authorization are different requirements. Train your front-end team to check both. A drug that clearly meets medical necessity under this policy can still hit a denial if prior auth wasn't obtained.

5. Review continued therapy cases for failure or intolerance flags.
If a patient's record documents a failed response or intolerance, and you're continuing to bill for that drug, your documentation needs to explain why. A more specific CPB may govern and provide a path forward — but CPB 0156 is the default, and it treats continued use after failure as not medically necessary.

6. Check the member's benefit plan for formulary and PBM restrictions.
CPB 0156 explicitly defers to plan-level restrictions. Before billing, verify the member's benefit plan doesn't impose additional limits beyond what CPB 0156 requires. Your billing guidelines should include a plan verification step for every Aetna commercial claim involving drug administration.

7. Loop in your compliance officer if you're uncertain about off-label combination therapy.
The combination therapy evidence standard is the most ambiguous part of this policy. If your practice regularly bills combination regimens where the evidence base is mixed or evolving, talk to your compliance officer before the January 22, 2026 effective date passes without a review.

---

CPT, HCPCS, and ICD-10 Codes for FDA-Approved Drug Indications Under CPB 0156

CPB 0156 does not list specific CPT, HCPCS, or ICD-10 codes. This policy sets the evidentiary framework for medical necessity across all FDA-approved drug claims under Aetna commercial plans. Code-level specificity is handled in drug-specific CPBs when they exist.

For FDA-approved drug billing, the codes that typically come into play depend on the drug, route of administration, and clinical setting. Your drug administration billing guidelines should reference the specific CPBs for individual drugs when available. When no drug-specific CPB exists, CPB 0156 is the governing standard.

If you're unsure which Aetna CPB governs a specific drug or indication, check the full CPB library at the source policy page and search by drug name or therapeutic category.

---